Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RGS4 | P49798 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 7/20 | 0.36 |
| ▸ | RAB9A | P51151 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.36 |
| ▸ | HTT | P42858 | 5/20 | 0.36 |
| ▸ | NR2F2 | P24468 | 2/20 | 0.36 |
| ▸ | RGS8 | P57771 | 4/20 | 0.34 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MITF | O75030 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 6/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.31 |
| ▸ | SLC2A1 | P11166 | 5/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL945029 | 0.98 | RAB9A (0.39) | RGS4LMNARAB9ASMN1; SMN2HTT | |
| SCHEMBL4114417 | 0.94 | RAB9A (0.37) | RGS4LMNARAB9ASMN1; SMN2HTT | |
| SCHEMBL3386346 | 0.74 | CNR1 (0.44) | RGS4SMN1; SMN2RGS8TSHRALDH1A1 | |
| SCHEMBL5278781 | 0.67 | CNR2 (0.39) | RGS4ALDH1A1CYP1A2CYP2C19 | |
| SCHEMBL3750688 | 0.65 | RAB9A (0.41) | RGS4LMNARAB9ASMN1; SMN2HTT | |
| Bromide SCHEMBL4940305 | 0.65 | CYP1A1 (0.48) | LMNARAB9ASMN1; SMN2HTTNR2F2 | |
| SCHEMBL9982876 | 0.65 | TNF (0.35) | TSHRTDP1L3MBTL1ALDH1A1KMT2A | |
| SCHEMBL964513 | 0.63 | POLB (0.39) | LMNARAB9ASMN1; SMN2HTTNR2F2 | |
| SCHEMBL4883169 | 0.60 | TSHR (0.50) | RGS4LMNASMN1; SMN2RGS8TSHR | |
| SCHEMBL11448924 | 0.60 | HSD11B1 (0.53) | RGS4LMNARAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865753-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-14 | — | — | US | disclosed |
| US-7875640-B2 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2011-01-25 | — | — | US | disclosed |
| CN-101765594-A | 1,3-thiazoles-2 (3H)-ylidene compounds as cannabinoid receptor ligand | ABBOTT LAB | 2010-06-30 | — | — | CN | disclosed |
| EP-2142522-A1 | 1, 3-THIAZOL-2 (3H) -YLIDENE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2010-01-13 | — | — | EP | disclosed |
| WO-2008121558-A1 | 1, 3-THIAZOL-2 (3H) -YLIDENE COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2008-10-09 | — | — | WO | disclosed |
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242654-A1 | N-[(2Z)-3-butyl-4,5-dimethyl-1,3-thiazol-2(3H)-ylidene]-5-chloro-N',2-dimethoxybenzenecarboximidamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | CNR2, CNR1, TRPV1 | RGS4 1294/4885LMNA 2741/4885RAB9A 3418/4885 |
| US-20110086832-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | RGS4 514/4885LMNA 3709/4885RAB9A 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.